Shandong Xinbo has completed the non clinical study of natural human monoclonal antibody CBB1 injection against rabies virus, helping to obtain clinical trial approval
2023/03/15
The Class 1 new drug developed by Changchun Baike Biotechnology Co., Ltd. - natural all human monoclonal antibody CBB1 injection against rabies virus has obtained clinical trial approval from the National Medical Products Administration.
The Drug Safety Evaluation Research Center of Shandong Xinbo Pharmaceutical Research Co., Ltd. has undertaken cross tissue studies, in vitro cytokine release studies, methodological establishment and validation, tissue distribution studies, and non clinical safety evaluation studies for this variety. The relevant research data provides support for the clinical trial approval of this variety.
